These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17416455)

  • 21. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
    BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Satraplatin for hormone-refractory prostate cancer.
    Kerr C
    Lancet Oncol; 2007 Apr; 8(4):290. PubMed ID: 17431954
    [No Abstract]   [Full Text] [Related]  

  • 23. [Role of mitoxantrone in the treatment of hormone-independent metastatic cancer of the prostate].
    Culine S
    Prog Urol; 2002 Feb; 12(1 Suppl 2):31-5. PubMed ID: 11980025
    [No Abstract]   [Full Text] [Related]  

  • 24. Tubulin-targeted agents including docetaxel and cabazitaxel.
    Cheetham P; Petrylak DP
    Cancer J; 2013; 19(1):59-65. PubMed ID: 23337758
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Therapy of painful bone metastases in patients with prostate carcinoma. The AP 32/02 Study of the AUO].
    Rexer H
    Urologe A; 2004 Sep; 43(9):1132-3. PubMed ID: 15487033
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
    Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI;
    Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Actual chemotherapeutical possibilities in hormone-refractory prostate cancer (HRPC) patients.
    Prezioso D; Galasso R; Di Martino M; Iapicca G; Annunziata E; Iacono F
    Anticancer Res; 2007; 27(2):1095-104. PubMed ID: 17465249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cycloplatam in the treatment of patients with disseminated prostatic cancer].
    Matveev BP; Gorbunova VA; Smirnova NB; Zhumagazin ZhD; Bukharkin BV; Orel NF
    Urol Nefrol (Mosk); 1996; (3):34-6. PubMed ID: 8928330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP
    Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How does sipuleucel-T alter our clinical practice?
    George D
    BJU Int; 2010 Oct; 106(7):945-6. PubMed ID: 20931691
    [No Abstract]   [Full Text] [Related]  

  • 32. Death of a clinical trial: a speculative inclusion criterion gone wrong.
    Rosenthal MA; Woo H; Gurney H; Copeman M; Zingarelli G
    Intern Med J; 2007 Dec; 37(12):838-9. PubMed ID: 18028092
    [No Abstract]   [Full Text] [Related]  

  • 33. New therapies for advanced prostate cancer: the nurse as part of the multidisciplinary team.
    Becze E
    ONS Connect; 2007; 22(8 Suppl):47-8. PubMed ID: 17824562
    [No Abstract]   [Full Text] [Related]  

  • 34. Should docetaxel be administered earlier in prostate cancer therapy?
    Graff JN; Beer TM
    Expert Rev Anticancer Ther; 2015; 15(9):977-9. PubMed ID: 26223224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Innovations in antineoplastic therapy.
    Kaplow R
    Nurs Clin North Am; 2005 Mar; 40(1):77-94. PubMed ID: 15733948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Other chemotherapy regimens including mitoxantrone and suramin.
    Siu LL; Moore MJ
    Semin Urol Oncol; 1997 Feb; 15(1):20-7. PubMed ID: 9050136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.
    Chi KN; Gleave ME; Klasa R; Murray N; Bryce C; Lopes de Menezes DE; D'Aloisio S; Tolcher AW
    Clin Cancer Res; 2001 Dec; 7(12):3920-7. PubMed ID: 11751483
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
    Petrylak D
    BJU Int; 2005 Dec; 96 Suppl 2():41-6. PubMed ID: 16359438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
    Oudard S; Banu E; Medioni J; Scotte F; Banu A; Levy E; Wasserman J; Kacso G; Andrieu JM
    BJU Int; 2009 Jun; 103(12):1641-6. PubMed ID: 19210673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of docetaxel based therapy for prostate cancer in the era of targeted medicine.
    Sonpavde G; Sternberg CN
    Int J Urol; 2010 Mar; 17(3):228-40. PubMed ID: 20088874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.